“Siddha medicine (widely practiced in South India) is effective against autism”

Siddha medicine, one of India's traditional medical systems and especially prominent in Tamil Nadu and South India, describes a condition called 'Mantha Sanni' that some practitioners and researchers consider closely related to autism spectrum disorder (ASD). Because Siddha formulations have long been used for this condition, and because a peer-reviewed clinical trial has now been published, some people present Siddha medicine as an effective, evidence-backed treatment for autism.

• A 2023 pilot clinical trial run at the National Institute of Siddha (Chennai, government-affiliated, ethics-approved and registered with the Clinical Trial Registry of India) tested two Siddha formulations — Amukkara chooranam (an oral herbal powder) and Yegamooli thylam (an external oil therapy) — in 30 children with ASD over 90 days, and found a statistically significant improvement in autism symptom scores (using the Indian Scale for Assessment of Autism) with no reported adverse effects.
• However, this trial had no control or comparison group and was not randomized or blinded — every child received the same treatment and was compared only to their own starting scores, not to children given a placebo or standard care. The study's own authors list the small sample size (30 children) as a key limitation and explicitly call for larger, randomized trials to confirm the results.
• Without a comparison group, this kind of before-and-after design cannot separate a real drug effect from other explanations: natural developmental progress over three months, the extra attention and monitoring participants received during the trial, parental expectation effects, or any other therapies families may have used alongside it.
• A broader systematic review of herbal medicine treatments for autism spectrum disorder (spanning multiple traditional systems, not just Siddha) reached a similar conclusion: results looked 'encouraging but were inconclusive owing to low methodological quality, herbal medicine diversity, and small sample size of the examined studies' — the same limitations seen in the Siddha trial.
• Siddha medicine is an officially recognized traditional medical system in India (part of the government's AYUSH framework) and the WHO has established a Global Centre for Traditional Medicine in India — but formal recognition as a traditional practice is a policy status, not proof that a specific formulation reliably treats a specific condition; that requires controlled clinical trials.
• No large-scale, randomized, placebo- or standard-care-controlled, blinded trial of Siddha therapeutics for autism currently exists — which is the type of evidence needed before a treatment can be confidently called 'effective.'

This claim sits in genuinely uncertain territory rather than being clearly true or false. Unlike fabricated or unstudied 'cure' claims, there is real, peer-reviewed, government-institution research specifically testing a Siddha treatment for autism, and it did find improvement. That's meaningfully different from having no evidence at all.

But the study design available so far — a single small group of 30 children, no comparison group, no blinding — cannot rule out the many other reasons symptom scores might improve over 90 days that have nothing to do with the herbal formulation itself. This is exactly the kind of preliminary result researchers describe as 'hypothesis-generating' rather than proof of efficacy: promising enough to justify a bigger, better-controlled study, but not strong enough on its own to say the treatment works. Broader reviews of herbal and traditional-medicine treatments for autism keep running into this same problem — small, poorly controlled studies that look encouraging but don't meet the bar for a confident conclusion. Until a randomized controlled trial is done, 'Siddha medicine is effective against autism' is an overstatement of what the current evidence actually shows.

• It's reasonable to view early Siddha research on autism as a promising area worth watching, not as a settled, proven treatment — the distinction matters when deciding how much to rely on it.
• If considering any traditional or herbal treatment alongside conventional autism support (speech therapy, occupational therapy, behavioral intervention), discuss it with your child's care team, particularly since herbal formulations can still have interactions or effects that haven't been studied in larger trials.
• The reported absence of adverse effects in the small trial is a modestly reassuring safety signal, but small studies are also underpowered to detect rare side effects — safety, like efficacy, needs larger trials to establish with confidence.

• This verdict reflects the current state of the specific clinical evidence for autism; it is not a broader judgment on Siddha medicine's value or safety for other conditions, some of which have more or different research behind them.
• Absence of strong proof is not the same as proof of no effect — it's possible a well-designed randomized trial could later confirm real benefit, just as it's possible it wouldn't. The honest answer right now is 'we don't know yet.'

• Efficacy of Siddha Therapeutics on Mantha Sanni (Autism Spectrum Disorder) Among Pediatric Patients: An Interventional Non-randomized Open-Label Clinical Trial — Cureus, 2023, DOI: 10.7759/cureus.47128
• Ancient Siddha Perspectives on Mantha Sanni and Its Relation to Autism Spectrum Disorder: A Comprehensive Review — Journal of Population Therapeutics and Clinical Pharmacology
• Herbal Medicine Treatment for Children with Autism Spectrum Disorder: A Systematic Review — PMC
• What Does Not Work: Beware of Non-Evidence-Based Treatments — Autism Science Foundation

• Augmentative and Alternative Communication (AAC) in Autism — Communication (Summary)
• Echolalia in Autism: What the Research Tells Us About Why Children Repeat Words and Phrases — Communication (Summary)
• Communication in Autism Spectrum Disorder: What the Research Tells Us — Communication (Summary)